Skip to main content
OpenTrials
Completed

NCT Number: NCT00689572

New Medication Treatment for Stimulant Dependence

This study will evaluate the efficacy of ondansetron compared with placebo in the treatment of cocaine dependence.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

University of Virginia Center for Addiction Research and Education, Charlottesville, Virginia, United States

Loading trial locations.

About this study

We propose to conduct a 9 week randomized, controlled clinical trial to evaluate the efficacy of ondansetron 4 mg twice daily compared with placebo (total N = 100/group × 2 groups = 200 individuals randomized, 400 total subjects will be consented), provided as an adjunct to manual-driven, structured CBT + BBCET in the treatment of cocaine dependence.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females who have given written informed consent.
  • Ages 18 years and above and, must weigh at least 40 Kg and no more than 140 Kg.
  • Good physical health as determined by a complete physical examination, an EKG within normal limits, and laboratory screening tests within acceptable parameters.
  • Current DSM-IV diagnosis of cocaine dependence.
  • At least one positive urine drug screen for cocaine at screen or baseline prior to randomization.
  • The pregnancy test for females at intake must be negative.
  • Literacy in English and ability to read, understand, and complete the ratings scales and questionnaires accurately, follow instructions, and make use of the behavioral treatments.
  • Answered an advertisement in the newspaper/radio/television, and expressing a wish to stop using cocaine.
  • Willing to participate in behavioral treatments for cocaine dependence.

Exclusion criteria

Please contact site for additional information

Treatment and study plan

ondansetron

Drug

4 mg twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy

Other names: Zofran

Placebo

Drug

twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy

Other names: Sugar Pill

Primary outcomes

  1. Cocaine Use by Self-report

    Time frame: up to 9 weeks

    Participants were assessed up to three times weekly for up to 9 weeks to evaluate cocaine use by self-report

  2. Cocaine Use by Urine Benzoylecgonine

    Time frame: up to 9 weeks

    Urine samples were collected up to three times weekly for up to 9 weeks to test for the major cocaine metabolite benzoylecgonine

Sponsors and collaborators

Lead sponsor

University of Virginia

Other

Collaborators

  • National Institute on Drug Abuse (NIDA)

Registry information

Important dates

Study start
2008
Primary completion
2013
Study completion
2013
First posted
Jun 3, 2008
Registry last updated
Nov 11, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.